Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 101–200 of 810
ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease
Lane-Donovan, C., & Herz, J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.12.001 · Cited by 157
“There is an enormous amount of literature that explores the interaction between ApoE4 and Aβ, which has been reviewed in depth recently in [1, 17, 18]; therefore, this review will focus on the roles of ApoE and its receptors at the synapse.”
BackgroundSelf-citationCellular cholesterol homeostasis and Alzheimer’s disease
Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155
“ApoE affects A aggregation and clearance in the brain in an isoform-specific manner (128, 129).”
BackgroundMolecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimer’s Disease
Harris, S. A., & Harris, E. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00048 · Cited by 148
“Apolipoproteins perform multiple functions within the brain related to lipid transport, regulation of lipidmetabolism, synaptic plasticity, cell signaling, and neuroinflammation (Holtzman et al., 2012).”
BackgroundBrain energy metabolism: Astrocytes in neurodegenerative diseases.
Chen, Z., Yuan, Z., Yang, S., Zhu, Y., Xue, M., Zhang, J., & Leng, L. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13982 · Cited by 153
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype
Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T. L. S., & Gordon, B. A. (2018) · Brain · doi:10.1093/brain/awy103 · Cited by 151
Self-citationThe role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)
Risacher, S. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00011 · Cited by 146
“Biochemically, APOE genotype has been shown to affect A β clearance rate, with the APOE ε 4 isoform showing significantly slower clearance (Deane et al., 2008; Castellano et al., 2011; Holtzman et al., 2012).”
BackgroundAmyloid β oligomers (AβOs) in Alzheimer’s disease
Mroczko, B., Groblewska, M., Litman‐Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1820-x · Cited by 157
β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 132
“Studies suggest that ApoE4 protein is less efficient than ApoE2 and ApoE3 in Aβ clearance [109].”
BackgroundMoraes, C. A., Santos, G., Spohr, T. C. L. D. S. E., D’Avila, J. C., Lima, F. R. S., Benjamim, C. F., Bozza, F. A., & Gomes, F. C. A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8868-5 · Cited by 145
Role of ABC Transporters in the Pathogenesis of Alzheimer’s Disease
Abuznait, A. H., & Kaddoumi, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300077c · Cited by 135
Fitz, N. F., Cronican, A. A., Saleem, M., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1937-12.2012 · Cited by 119
“There are numerous reports demonstrating that ApoE binds A (Wisniewski and Frangione, 1992; Strittmatter et al., 1993; LaDu et al., 1994), but it is still unclear how this binding affects A aggregation (for review, see Kim et al., 2009; Holtzman et al., 2012).”
BackgroundNeuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142
The endosomal-lysosomal pathway is dysregulated by APOE4 expression in vivo
Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., Ambat, J., Levy, E., Cookson, M. R., Mathews, P. M., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00702 · Cited by 140
“…E, APOE, APOE4, endosome, lysosome, Alzheimer’s disease, transcriptomics, RNA-seq INTRODUCTION Apolipoprotein E (APOE) plays a vital role in the transport of cholesterol and other lipids through the bloodstream, as well as within the brain (Mahley and Rall, 2000; Han, 2004; Holtzman et al., 2012).”
BackgroundImpaired Autophagy in APOE4 Astrocytes
Simonovitch, S., Schmukler, E., Bespalko, A., Iram, T., Frenkel, D., Holtzman, D. M., Masliah, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151101 · Cited by 136
“For example, ApoE receptors such as LRP and ApoER2, which play important roles in key cellular processes [45, 46], were shown to be affected differentially by ApoE4 and ApoE3 [47, 48].”
Self-citationAPOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
Sampedro, F., Initiative, F. T. A. D. N., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5185 · Cited by 135
“Both ß-amyloid-dependent [20] and ß-amyloid-independent [21] mechanisms have been described.”
BackgroundShi, Y., Andhey, P. S., Ising, C., Wang, K., Snipes, L. L., Boyer, K., Lawson, S., Yamada, K., Qin, W., Manis, M., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.034 · Cited by 135
Self-citationMahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00516-0 · Cited by 134
“The influence of APOE on AD risk occurs in an isoform-dependent manner (ε2 ε3 ε4) [3–6].”
BackgroundSelf-citationApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation
Sen, A., Nelson, T. J., & Alkon, D. L. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0260-15.2015 · Cited by 133
“LDLR and LRP-1 are the main ApoE lipoprotein metabolic receptors in the brain (Koryakina et al., 2009; Holtzman et al., 2012; Liu et al., 2013), and we previously showed that ApoE3 protects against ASPD-induced synaptic damage through LRP-1 (Sen et al., 2012).”
BackgroundIntercellular Spread of Protein Aggregates in Neurodegenerative Disease
Davis, A. A., Leyns, C. E. G., & Holtzman, D. M. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062636 · Cited by 131
“By far the most detailed understanding of this process exists for Aβ, for which lipoprotein receptors, including LRP1 and LDLR, appear to participate in clearance of Aβ across the blood-brain barrier, likely through multiple mechanisms, including some involving apoE (Holtzman et al. 2012).”
BackgroundSelf-citationCalderón-Garcidueñas, L., Franco-Lira, M., Mora-Tiscareño, A., Medina-Cortina, H., Torres-Jardón, R., & Kavanaugh, M. (2013) · BioMed Research International · doi:10.1155/2013/161687 · Cited by 121
“The differential effects of ApoE isoforms on AD risk are given at least in part by the ability to affect Aβ aggregation and clearance in the brain, effects on synaptic plasticity, cell signaling, lipid transport andmetabolism, and neuroinflammation [78].”
HSV-1 and Alzheimer’s disease: more than a hypothesis
Piacentini, R., De Chiara, G., Li Puma, D. D., Ripoli, C., Marcocci, M. E., Garaci, E., Palamara, A. T., & Grassi, C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00097 · Cited by 130
“Differently from the other three variants, ApoE4 exhibits scarce ability to bind Aβ, thus its expression contributes to Aβ accumulation and aggregation inside neurons and influences the formation of the parenchymal amyloid plaques (Holtzman et al., 2012; Verghese et al., 2013).”
BackgroundMeasuring cognition and function in the preclinical stage of Alzheimer's disease
Weintraub, S., Carrillo, M. C., Farias, S. T., Goldberg, T. E., Hendrix, J. A., Jaeger, J., Knopman, D. S., Langbaum, J. B., Park, D. C., Ropacki, M. T., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.01.003 · Cited by 120
“Amyloid deposition is associated also with the apolipoprotein E (APOE) ε4 genotype [5] and with greater decline in cognitive function over time [6].”
BackgroundIn vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
Ulrich, J. D., Burchett, J. M., Restivo, J. L., Schuler, D. R., Verghese, P. B., Mahan, T. E., Landreth, G. E., Castellano, J. M., Jiang, H., Cirrito, J. R., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-13 · Cited by 128
“Previous studies indicate that apoE affects the metabolism and oligomerization of Aβ within the brain [3,4,24] as well as influences a variety of other biological processes [2].”
BackgroundInfluentialSelf-citationABCA7 and Pathogenic Pathways of Alzheimer’s Disease
Aikawa, T., Holm, M.-L., & Kanekiyo, T. (2018) · Brain Sciences · doi:10.3390/brainsci8020027 · Cited by 124
Hinrich, A. J., Jodelka, F. M., Chang, J. L., Brutman, D., Bruno, A. M., Briggs, C. A., James, B. D., Stutzmann, G. E., Bennett, D. A., Miller, S. A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505846 · Cited by 127
“…Splicing; Therapeutics Subject Categories Neuroscience; Pharmacology & Drug Discovery DOI 10.15252/emmm.201505846 | Received 10 September 2015 | Revised 25 January 2016 | Accepted 27 January 2016 | Published online 22 February 2016 EMBO Mol Med (2016) 8: 328–345 See also: CR Wasser & J Herz…”
InfluentialMitochondria and Calcium Regulation as Basis of Neurodegeneration Associated With Aging
Müller, M., Ahumada-Castro, U., Sanhueza, M., Gonzalez-Billault, C., Court, F. A., & Cárdenas, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00470 · Cited by 124
“Remarkably, one of the most common and validated risk factors for SAD, the presence of APOE4 (Holtzman et al., 2012), has recently been associated with an increase in the ER–mitochondrial communication and MAM enzymatic activity (Tambini et al.”
BackgroundEpigenomics of Alzheimer's disease
Bennett, D. A., Yu, L., Yang, J., Srivastava, G. P., Aubin, C., & De Jager, P. L. (2015) · Translational Research · doi:10.1016/j.trsl.2014.05.006 · Cited by 123
Role of BACE1 in Alzheimer’s synaptic function
Das, B., & Yan, R. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0093-5 · Cited by 121
The Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
Zhang, X., Fu, Z., Meng, L., He, M., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00359 · Cited by 122
“Besides, ApoE also plays a role in mediating synaptogenesis, synaptic plasticity and neuroinflammation (Holtzman et al., 2012).”
BackgroundClinical and imaging features of mixed Alzheimer and vascular pathologies
Chui, H. C., & Ramirez-Gomez, L. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0104-7 · Cited by 124
“brain: 1) enzymatic degradation (for example, neprilysin, insulin degrading enzyme) by microglia and astrocytes; 2) active transport from brain to blood through an endothelial lipoprotein receptor-related protein-mediated process [55-57]; and 3) passive transport through a perivascular ‘lymphatic-like’ drainage system…”
BackgroundReduction in DHA transport to the brain of mice expressing human APOE 4 compared to APOE 2
Vandal, M., Alata, W., Tremblay, C., Rioux‐Perreault, C., Salem, N., Calon, F., & Plourde, M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12640 · Cited by 110
25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner
Wong, M. Y., Lewis, M., Doherty, J. J., Shi, Y., Cashikar, A. G., Amelianchik, A., Tymchuk, S., Sullivan, P. M., Qian, M., Covey, D. F., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01869-3 · Cited by 121
Self-citationLeveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 126
Liraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118
“The finding that other components of the glutamatergic synapse, such as synaptic spines [65], postsynaptic glutamatergic receptors [64,68], and the scaffold protein PSD-95 [69] are decreased by apoE4 suggests that the presently observed apoE4-driven decrease in VGlut is not specific to this molecule and is associated…”
BackgroundCarlo, A.-S., Gustafsen, C., Mastrobuoni, G., Nielsen, M. S., Burgert, T., Hartl, D., Rohe, M., Nykjaer, A., Herz, J., Heeren, J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2425-12.2013 · Cited by 117
Self-citationDhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 123
Song, Q., Song, H., Xu, J., Huang, J., Hu, M., Gu, X., Chen, J., Zheng, G., Chen, H., & Gao, X. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00781 · Cited by 113
Relative risk for Alzheimer disease based on complete family history
Cannon‐Albright, L., Foster, N. L., Schliep, K. C., Farnham, J. M., Teerlink, C. C., Kaddas, H. K., Tschanz, J. T., Corcoran, C., & Kauwe, J. S. K. (2019) · Neurology · doi:10.1212/wnl.0000000000007231 · Cited by 132
ElAli, A., & Rivest, S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00045 · Cited by 108
“As such, highly lipidated ApoE binds more efficiently Aβ and diminishes its capacity to aggregate by modulating its conformation (Wahrle et al., 2004; Holtzman et al., 2012).”
BackgroundCalcium-Handling Defects and Neurodegenerative Disease
Schrank, S., Barrington, N. M., & Stutzmann, G. E. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035212 · Cited by 122
Grimm, M. O. W., Michaelson, D. M., & Hartmann, T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076331 · Cited by 109
Heffernan, A. L., Chidgey, C., Peng, P., Masters, C. L., & Roberts, B. R. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0804-x · Cited by 113
Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Amemori, T., Jendelova, P., Ruzicka, J., Urdzikova, L., & Sykova, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125961 · Cited by 102
Lautner, R., Palmqvist, S., Mattsson, N., Andreasson, U., Wallin, A., Pålsson, E., Jakobsson, J., Herukka, S.-K., Owenius, R., Olsson, B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1060 · Cited by 107
“Simultaneous measurement of betaamyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.”
BackgroundMethodZhan, X., Jickling, G. C., Ander, B. P., Stamova, B., Liu, D., Kao, P. F., Zelin, M. A., Jin, L.-W., DeCarli, C., & Sharp, F. R. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142013 · Cited by 102
“LRP1 is a major receptor for A PP endocytosis [62] and a major efflux transporter for A across the blood-brain barrier [63].”
APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease
Reinvang, I., Espeseth, T., & Westlye, L. T. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.006 · Cited by 105
Zádori, D., Veres, G., Szalárdy, L., Klivényi, P., & Vécsei, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170929 · Cited by 107
“contributes to the pathogenic processes by disrupting neurogenesis, cholesterol metabolism, AβPP processing, the degradation of Aβ, tau hyperphosphorylation, and other cellular pathways, including mitochondrial function and synaptic plasticity [70-73].”
Zhao, L., Gottesdiener, A. J., Parmar, M., Li, M., Kaminsky, S. M., Chiuchiolo, M. J., Sondhi, D., Sullivan, P. M., Holtzman, D. M., Crystal, R. G., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.020 · Cited by 107
“…recognized as very early events in the pathogenesis of AD, that is, these are neuropathologic features that are now known to occur many years before the onset of cognitive impairment and dementia (Hardy and Selkoe, 2002; Holtzman et al., 2012; Kim et al., 2009; Liu et al., 2013; Yu et al., 2014).”
InfluentialSelf-citationIs Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum
Ríos, J. A., Cisternas, P., Arrese, M. A., Salesa Barja, Y., & Inestrosa, N. C. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.07.004 · Cited by 109
“clearance is due to the failure of the interaction of ApoE4 with its receptor, LRP1 (Holtzman et al., 2012), because the levels of this”
BackgroundDiversity of satellite glia in sympathetic and sensory ganglia
Mapps, A. A., Thomsen, M. B., Boehm, E. D., Zhao, H., Hattar, S. S., & Kuruvilla, R. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110328 · Cited by 115
An ancestral recombination graph of human, Neanderthal, and Denisovan genomes
Schaefer, N. K., Shapiro, B., & Green, R. E. (2021) · Science Advances · doi:10.1126/sciadv.abc0776 · Cited by 106
Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
APP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
“In humans there are three different ApoEε alleles encoding for the isoforms ApoEε2, ApoEε3 and ApoEε4 (Weisgraber et al., 1981; Mahley et al., 1996; Holtzman et al., 2012).”
BackgroundMuszyński, P., Groblewska, M., Kulczyńska-Przybik, A., Kułakowska, A., & Mroczko, B. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170208124324 · Cited by 99
“In comparison to subjects without ε4 allele, the elevated risk for AD tends to be almost three-fold higher in people with one ε4 allele and twelve-fold higher in those who inherited two ε4 allele [16].”
BackgroundJeong, W., Lee, H. G., Cho, S., & Seo, J. (2019) · PubMed · doi:10.14348/molcells.2019.0200 · Cited by 105
“It is also important to investigate whether ApoE4 neurons have altered the expression and/or function of ApoE receptors such as those belonging to the low-density lipoprotein receptor family that can directly affect the uptake of extracellular cholesterol as well as Aβ clearance (Holtzman et al., 2012).”
BackgroundOrr, A. L., Kim, C., Jimenez-Morales, D., Newton, B. W., Johnson, J. R., Krogan, N. J., Swaney, D. L., & Mahley, R. W. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181184 · Cited by 103
Impact of Apolipoprotein E on Alzheimer’s Disease
Hauser, P., & Ryan, R. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990156 · Cited by 102
“Alternatively, Aβ may be subject to receptor-mediated clearance through interaction with members of the low density lipoprotein receptor (LDLR) family, including the LDLR, the low-density lipoprotein receptor related protein 1 (LRP1) or the very low density lipoprotein receptor (VLDLR) [3, 4]; (Fig.”
BackgroundCheng, H., Wang, M., Li, J., Cairns, N. J., & Han, X. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12368 · Cited by 103
Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Hubin, E., van Nuland, N. A. J., Broersen, K., & Pauwels, K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1634-z · Cited by 104
“The modulation of Aβ production, aggregation, and degradation by environmental factors [155–157], genetic risk factors [158–161], post-translational modifications [127], and an individual’s lifestyle [162–169] has been extensively reviewed before and does not lie in the scope of this review.”
BackgroundPlaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
“org higher risk of AD, and an earlier age of symptom onset), but it has no or little effect on pathologic processes downstream of Ab.(25) Although they should be viewed as preliminary, given the modest sample size and that complex interactions among the variables may not have been adequately modeled, some interesting…”
BackgroundHigh-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 112
“The putative roles of apoE and its isoform-specific effects on AD pathogenesis have been well studied, though there is still much to learn (Holtzman et al., 2012).”
BackgroundThe interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease
Jazvinšćak Jembrek, M., Slade, N., Hof, P. R., & Šimić, G. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.05.001 · Cited by 100
“It is interesting that receptors for ApoE act as signalling molecules able to modulate phosphorylation of various proteins following extracellular ligand binding, which in the end may affect microtubule stability and synapse formation, and ultimately contribute to AD pathology (Nathan et al., 1995; Hoe et al., 2006; H…”
Yamanaka, Y., Faghihi, M. A., Magistri, M., Alvarez-Garcia, O., Lotz, M., & Wahlestedt, C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.011 · Cited by 99
“Recently, LRP1 has been implicated in the systemic clearance of AD amyloid-beta (Ab), and the level of LRP1 expression is critical for AD progression (Deane et al., 2008; Holtzman et al., 2012; Kang et al., 2000; Liu et al., 2007; Shibata et al., 2000).”
BackgroundContribution of Trimethylamine N-Oxide (TMAO) to Chronic Inflammatory and Degenerative Diseases
Constantino-Jonapa, L. A., Espinoza-Palacios, Y., Escalona‐Montaño, A. R., Hernández-Ruiz, P., Amezcua-Guerra, L. M., Amedei, A., & Aguirre‐García, M. M. (2023) · Biomedicines · doi:10.3390/biomedicines11020431 · Cited by 102
“The ε4 allele of the apoE gene increases the risk of Alzheimer’s disease, while the ε2 allele provides protection against it [118].”
Kumar, N., Kumar, V., Anand, P., Kumar, V., Dwivedi, A. R., & Kumar, V. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116742 · Cited by 105
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“This observation was also confirmed in genetically engineered mice [10].”
BackgroundAmidi, A., Agerbæk, M., Wu, L. M., Pedersen, A. D., Mehlsen, M., Clausen, C. R., Demontis, D., Børglum, A. D., Harbøll, A., & Zachariae, R. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9552-3 · Cited by 95
Lyall, D. M., Cox, S. R., Lyall, L. M., Celis-Morales, C., Cullen, B., Mackay, D. F., Ward, J., Strawbridge, R. J., McIntosh, A. M., Sattar, N., et al. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00069-9 · Cited by 97
Reelin protects against amyloid β toxicity in vivo
Lane-Donovan, C., Philips, G. T., Wasser, C. R., Durakoglugil, M. S., Masiulis, I., Upadhaya, A., Pohlkamp, T., Coskun, C., Kotti, T., Steller, L., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa6674 · Cited by 96
“Because ApoE4 also promotes AD pathogenesis through other mechanisms [for example, increasing inflammatory processes, increasing tau phosphorylation, and reducing clearance ofAb (67)], we sought to isolate the effects of Reelin loss on the background of increasing Ab accumulation, which occurs in the early stages of A…”
BackgroundSelf-citationNew fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Park, S. A., Han, S. M., & Kim, C. E. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0418-9 · Cited by 91
The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease
Malnar, M., Hecimovic, S., Mattsson, N., & Zetterberg, H. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.033 · Cited by 89
“This variant of ApoE, the main protein carrier for cholesterol in the brain, remains a major risk factor for late onset AD and is the main reason for why lipid metabolism remains in focus of AD research (Holtzman et al., 2012).”
Taylor, X., Cisternas, P., You, Y., You, Y., Xiang, S., Marambio, Y., Zhang, J., Vidal, R., & Lasagna-Reeves, C. A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01900-7 · Cited by 91
Litvinchuk, A., Huynh, T. V., Shi, Y., Jackson, R. J., Finn, M. B., Manis, M., Francis, C. M., Tran, A. C., Sullivan, P. M., Ulrich, J. D., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26043 · Cited by 91
Self-citationRecent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160882 · Cited by 84
Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomovic, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 86
Skerrett, R., Pellegrino, M. P., Casali, B. T., Taraboanta, L., & Landreth, G. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.652008 · Cited by 88
“Upon ligand binding, LXRs form obligate heterodimers with retinoid X receptors (RXRs) and promote the transcription of apoE, ABCA1, and ABCG1, among other genes involved in cholesterol metabolism (16).”
BackgroundInfluentialYao, L., Gu, X. Q., Song, Q., Wang, X., Huang, M., Meng, H., Hou, L., Kang, T., Chen, J., Chen, H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.055 · Cited by 93
Agostinho, P., Pliássova, A., Oliveira, C. R., & Cunha, R. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142730 · Cited by 85
“The trafficking of A!PP can also be regulated by the low-density lipoprotein receptor family that also act as receptors for ApoE, which allelic polymorphisms are strongly associated with the onset of AD [65, 66].”
BackgroundLipid Rafts in Neurodegeneration and Neuroprotection
Sonnino, S., Aureli, M., Grassi, S., Mauri, L., Prioni, S., & Prinetti, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8614-4 · Cited by 96
Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan
Fouquet, M., Besson, F. L., Gonneaud, J., Joie, R. L., & Chételat, G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9263-8 · Cited by 95
“This gene codes for a lipoprotein called apolipoprotein E that plays a role in the transport of lipids (see Bu 2009; Holtzman et al. 2012 for reviews).”
BackgroundRole of lncRNAs in aging and age‐related diseases
He, J., Tu, C., & Liu, Y. (2018) · Aging Medicine · doi:10.1002/agm2.12030 · Cited by 91
Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma
Rajora, M. A., Ding, L., Valic, M., Jiang, W., Overchuk, M., Chen, J., & Zheng, G. (2017) · Chemical Science · doi:10.1039/c7sc00732a · Cited by 84
Del Prete, D., Rice, R. C., Rajadhyaksha, A. M., & D'Adamio, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.733626 · Cited by 86
“Group 3: this group includes the tubulin-binding protein Tau (93) and the cholesterol transporter apoE (94).”
BackgroundSong, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114647 · Cited by 97
Landry, G. J., & Liu-Ambrose, T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00325 · Cited by 84
“The amyloid hypothesis gained credence with the discovery that the apolipoprotein E (APOE) genotype is the strongest genetic risk factor for AD (for reviews see Kim et al., 2009; Holtzman et al., 2012).”
BackgroundCould Alzheimer’s Disease Originate in the Periphery and If So How So?
Morris, G., Berk, M., Maes, M., & Puri, B. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1092-y · Cited by 83
“Genome-wide association studies (GWASs) have revealed that approximately 40% of AD patients carry the apolipoprotein E (APOE) ε4 allele and that APOE ε4-positive, but cognitively intact, individuals over 50 years of age are significantly more likely to have brain amyloid deposits than individuals free of that polymorp…”
BackgroundAPOE and neuroenergetics: an emerging paradigm in Alzheimer's disease
Wolf, A. B., Caselli, R. J., Reiman, E. M., & Valla, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.011 · Cited by 79
“Current evidence supports APOEencoded apolipoprotein E (apoE) isoforms differentiallymodulating b-amyloid aggregation and clearance (Bu, 2009; Holtzman et al., 2012; Kim et al., 2009).”
BackgroundA Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
Manzano, S., Agüera, L., Aguilar, M., & Olazarán, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00614 · Cited by 87
“ApoE protein binds to soluble Aβ and affects aggregation, transport, and clearance of amyloid within the central nervous system (CNS), increasing Aβ oligomers in the brain, which would contribute to the loss of dendritic spines thus acceleratingmemory impairment and leading to earlier cognitive decline in AD (16, 19,…”
BackgroundApoE-2 Brain-Targeted Gene Therapy Through Transferrin and Penetratin Tagged Liposomal Nanoparticles
dos Santos Rodrigues, B., Kanekiyo, T., & Singh, J. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2691-7 · Cited by 81
APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
The role of long non-coding RNAs in the pathogenesis of hereditary diseases
Sparber, P. A., Filatova, A. Y., Khantemirova, M., & Skoblov, M. Y. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0487-6 · Cited by 86
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
“Several receptors of the low density lipoprotein receptor (LDLR) family have been shown to bind apoE, A , and APP, and thereby could affect both generation and degradation of A (67, 75, 76).”
BackgroundAmyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights
Das, M., & Gursky, O. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_8 · Cited by 92
“Plasma apoE circulates mostly on VLDL where it serves as a ligand for LDL-like receptor that mediates VLDL uptake and, ultimately, maturation to LDL (Hauser et al. 2011; Holtzman et al. 2012).”
BackgroundNew Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Saito, S., & Ihara, M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00290 · Cited by 73
“ApoE immunoreactivity is common in amyloid plaques, suggesting that ApoE interacts with Aβ directly in AD brains and could strongly influence the rate of Aβ removal (Namba et al., 1991; Holtzman et al., 2012).”
BackgroundGenetic variants of ApoE and ApoER2 differentially modulate endothelial function
Ulrich, V., Konaniah, E. S., Herz, J., Gerard, R. D., Jung, E., Yuhanna, I. S., Ahmed, M., Hui, D. Y., Mineo, C., & Shaul, P. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402106111 · Cited by 76
“Whereas there is considerable understanding of the biology of the apoE–ApoER2 tandem in the central nervous system and in Alzheimer’s disease (10), the basis for the cardiovascular impact of the receptor and apoE variants remains unclear.”
BackgroundSelf-citationNeuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
Wirths, O., & Zampar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218144 · Cited by 75
Abushakra, S., Porsteinsson, A., Scheltens, P., Sadowsky, C., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Wang, P., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.26 · Cited by 75
Mann, C. N., Devi, S. S., Kersting, C. T., Bleem, A. V., Karch, C. M., Holtzman, D. M., & Gallardo, G. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm4107 · Cited by 73
“In addition, recent studies further demonstrated the networking between microglia and astrocytes in a tauopathy mouse model expressing human Apoe4, the strongest genetic risk factor for AD (57).”
BackgroundSelf-citation
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.